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INTRODUCTION
An  increasing  number  of  childhood  cancer  survivors  have  led  to  a  heightened 
appreciation of the late complications caused by the disease and its treatment. In the USA, 5-
year survival for all type of childhood cancers increased from 51% in 1973 to79% in 1997 [1] 
Incidence of childhood cancer in India is 9 per million [2]. Advances in multimodality therapy 
have dramatically improved the cure rates of pediatric cancers in the past 2 decades. 5 year 
survival rates for childhood cancers have also improved in our country [3].
The therapy responsible for this survival can also produce adverse long-term health-
related outcomes that manifest months to years after completion of cancer treatment, and are 
commonly referred to as late effects. 
Risk factors for late effects include: [4]
Tumor-related factors 
o Direct tissue effects. 
o Tumor-induced organ dysfunction. 
o Mechanical effects.
Treatment-related factors 
o Radiation  therapy: Total  dose  and fraction  size,  organ  or  tissue  volume,  and 
machine energy are the most critical factors. 
o Chemotherapy: Agent type, single and cumulative dose and schedule may modify 
risk. 
o Surgery: Technique and site are relevant.
Host-related factors 
o Developmental status. 
o Genetic predisposition. 
o Inherent tissue sensitivities and capacity for normal tissue repair. 
o Function of organs not affected by radiation therapy or chemotherapy. 
o Premorbid state.
Late  effects  include  organ  dysfunction,  second  malignant  neoplasm,  and  adverse 
psychosocial sequelae [5]. 
Monitoring after childhood cancer should have two main goals:
 1) to confirm continued remission and 
 2) to monitor for late effects of cancer or its therapy.
Although survival rates of childhood cancer have steadily increased in our country there 
is paucity of data regarding long term follow up of survivors. The purpose of this study was to 
determine  the  long  term  sequale  associated  with  therapy  in  childhood  cancer  survivors 
attending a regional cancer centre in India.
AIM
This study was designed to identify adverse late effects of both cancer and its therapy 
among childhood cancer survivors.
REVIEW OF LITERATURE
Childhood cancers exhibit greater diversity in terms of anatomical site and histologic 
type than adult  cancers,  where carcinomas of the breast,  lung and gut predominate.  Of all 
childhood  cancers,  approximately  one  third  are  leukemias  and  80%  of  these  are  Acute 
lymphoblastic  leukemia  (ALL),  25%  are  brain  and  spinal  tumours,  15%  are  embryonal 
tumours, 11% are lymphomas and the remainder is comprised of bone and other rare tumours 
in western population.[6] In our hospital cancer registry, Cancer Institute, Chennai data from 
1998-2002, among pediatric cancers 37% are leukemia, 34% lymphomas and 12% bone and 
soft tissue sarcoma, eye and brain tumors are 17%.[7]
The  last  three  decades  have  seen  tremendous  improvements  in survival  of  children 
diagnosed with cancer, with the 5-year survival rate approaching 80%. This improvement in 
survival has resulted in a growing population of childhood cancer survivors.
In 1997, there were an estimated 270,000 survivors of childhood cancer in the US, with 
1  in  1000  individuals  being a  childhood  cancer  survivor.2 Demographics  of  the  childhood 
cancer survivors in the US reveal that while a third of these survivors are still less than 20 years 
of age, 46% are between 20 and 40 years old and an additional 18% are over 40 years of age 
[8].
Table-1: 5 year survival rates (%) in childhood cancers from 1962-1996. (Source- National 
Registry of Childhood Tumours-Scotland) [6] 
1962-6
6
1967-7
1
1972-7
6
1977-8
1
1982-8
6
1987-9
1
1992-9
6
ALL 4 17 44 56 70 75 81
AML 2 2 7 17 30 47 54
Brain tumours 37 37 43 48 54 57 68
Ewings 25 23 40 34 45 68 61
GCT 55 52 56 74 90 94 96
Hodgkins 39 68 81 89 89 93 94
NHL 17 21 26 45 67 76 78
Neuroblastoma 18 17 19 31 43 41 53
Retinoblastoma 88 86 88 88 89 93 94
RMS 25 23 33 44 58 59 66
Wilms 29 43 62 76 80 82 80
ALL CANCERS 24 29 42 51 62 67 73
Abbreviation  
ALL- Acute Lymphoblastic leukemia, AML- Acute myeloid leukemia,GCT- germ cell 
tumours ,NHL – Non Hodgkin lymphoma , RMS - Rhabdomyosarcoma
Large epidemiological studies have analyzed the subsequent mortality and its causes in 
children and adolescents who survived five years from the diagnosis of cancer. Two studies 
found that 5-year survivors of childhood cancer have a standardized mortality ratio (SMR) of 
11 (ie an 11 fold increased risk of death in subsequent years when compared with age and sex 
specific expected rates for the general population[9] . A North American study comprising of 
20,227  5  year  childhood  cancer  survivors  diagnosed  between  1970  and  1986  showed  a 
significantly higher SMR of 18 in female survivors, individuals diagnosed with cancer before 
the age of 5 years (SMR=14) and those with an initial diagnosis of leukemia (SMR=15.5) and 
central  nervous  system  tumour  (SMR=15.7).  The  leading  cause  of  death  among  5  year 
survivors was recurrence of the original cancer with a statistically significant excess mortality 
rate  seen  due  to  subsequent  malignancies  (SMR=19.4)  as  well  as  cardiac  (SMR=8.2), 
pulmonary  (SMR=9.2)  and  other  causes  (SMR=3.3).  There  was  no  excess  mortality  from 
external causes like road traffic accidents. These studies provide a resource for understanding 
how mortality may be reduced further, and how modifications of current therapy may reduce 
treatment related mortality in the future [9].
Curry et al in their childhood survivor study noted that 61 % of survivors have one or 
more chronic medical problems and require multidisciplinary care [10] and about one third will 
experience a late effect that is severe or life threatening.
Common late effects  based on treatment modality  are  as  described in the  following 
tables [11].
Table 2 Late Effects of Chemotherapy
Organ/
Tissue
Predisposing drug(s) Late Effect
Brain Methotrexate, Cytarabine 
(high dose, intrathecal)
Leukoencephalopathy, 
neurocognitve dysfunction, 
seizures
Nerves Cisplatin,
Vincristine,Vinblastine
Hearing loss
Peripheral neuropathy, foot 
drop
Heart Anthracyclines
Cyclophosphamide (high 
dose)
Cardiomyopathy
Cardiac failure. arrythmias
Lungs Bleomycin, 
BCNU,Cyclophosphamide
Pulmonary fibrosis
Liver Methotrexate. BCNU Hepatitis, Hepatic fibrosis
Kidney Cisplatin, Ifosphamide
high dose methotrexate, 
Nitosureas
Renaltubular dysfunction,
Hypomagnesemia
Reduced renal filtration, 
Renal failure (rare)
Bladder Ifosphamide, 
Cyclophosphamide
Haemorrhagic cystitis, 
Bladder fibrosis, Carcinoma 
bladder
Testes 
and 
Ovaries
Alkylating agents 
(Chlorambucil, 
Cyclophosphamide, 
procarbazine, BCNU, CCNU)
Females: Low estrogen 
levels, ovarian failure, 
Infertility, early menopause
Males:azoospermia, 
infertility, Hypogonadism
Bone 
marrow
Alkylating agents, etoposide, 
tenoposide
Myelodysplasia, t-AML
Bones Corticosteroids, methotrexate Osteoporosis, avascular 
necrosis
Skin Bleomycin, dactinomycin Hyperpigmentation
Table 3 Late effects of Radiation Therapy
Field Late effects
All tissues Second malignancies, skin fibrosis
Cranial Neurocognitive  deficits,  endocrinopathies, 
abnormal  tooth  development,  dental  caries, 
infertility, cataract
Spinal thyroid dysfunction, kyphoscoliosis, myelitis
Head and neck Dental  caries,  thyroid  dysfunction,  hearing  loss, 
cataracts,  osteoradionecrosis,  maxillary  or 
mandibular hypoplasia, xerostomia
Orbit Cataract,  corneal  ulcer,  keratitis,  orbital 
hypoplasia, glaucoma, blepharitis
Mediastinum, 
pulmonary, Mantle
Cardiomyopathy,  pericarditis,  coronary  and 
valvular  heart  disease,  arrythmias,  pulmonary 
fibrosis, breast hypoplasia, esophageal stricture
Abdominal Hepatic fibrosis, esophageal varices, renal damage, 
renal  artery  stenosis,  scoliosis,  intestinal  fibrosis, 
malabsorption
Testicular Leydigs cell failure.infertility
Pelvic Gonadal  failure,  marrow hypoplasia,  bladder  and 
ureteral  fibrosis,  urethral  strictures,  vaginal 
fibrosis, hemorrhagic cystitis
Extremity Growth  discrepancy,  pathological  fractures, 
muscular hypoplasia, necrosis
Total Body 
Irradiation
Growth  failure,  hypothyroidism,  gonadal  failure, 
cataracts
Table 4  Late Effects of Surgery
Surgery Late Effect
Limb salvage Pathological  fractures,  limited  movements,  graft 
infection, loosening of prosthesis
Amputation Prosthesis  and  stump  complications,  cosmetic 
deformity, psychosocial effects
Laparotomy Fistulas, bowel obstruction
Nephrectomy Hypertension and renal dysfunction
Orchidectomy, 
Oopherectomy
Gonadal failure
Splenectomy Impaired  immune  function,  overwhelming  sepsis 
(encapsulated bacteria)
Thyroidectomy Hypothyroidism
Enucleation Prosthesis complications and blindness
Common Late Effects of Childhood Cancer by Body System 
Central Nervous System
Neurocognitive 
Neurocognitive  late  effects  most  commonly  follow  treatment  of  malignancies  that 
require  central  nervous  system  (CNS)-directed  therapies,  such  as  cranial  radiation  or 
intraventricular/intrathecal (IT) chemotherapy; thus, children with CNS tumors, head and neck 
sarcomas, and acute lymphoblastic leukemia (ALL) are most commonly affected [12]. Deficits 
occur in a variety of areas that include the following
General intelligence. 
• Age-appropriate developmental progress. 
• Academic achievement (especially in reading, language, and mathematics). 
• Visual and perceptual motor skills. 
• Nonverbal and verbal memory. 
• Receptive and expressive language and attention. 
For ALL, studies again show significant neurocognitive impairment [13]. Even when 
combined with intrathecal chemotherapy, reduction in the cranial radiation dose has resulted in 
less neurocognitive impairment [14]. Deficits in fine motor skills, visual-spatial abilities, verbal 
and nonverbal memory, psychomotor speed and shifting of attention, auditory perception, word 
fluency, contingency naming, and the ability to follow directions have all been reported [15].
Copeland et al.  showed combined treatment is associated with more severe cognitive 
and academic deficits than CNS chemotherapy alone [16]. In this and the other studies cited, 
children were treated with high dose (2400 cGy) radiotherapy. There is some evidence that low 
dose cranial irradiation (i.e., 1800 cGy) has a milder effect on cognitive functioning than higher 
doses  .Irradiation-or  chemotherapy-induced  destruction  in  normal  white  matter  partially 
explains intellectual and academic achievement deficits [17]. Combined-therapy participants 
had significantly smaller amplitude and slower response of the P-300 (a brain-evoked potential 
associated with attention) The function of myelin is to increase axonal conduction velocity, the 
results of this study suggest that the effect of CRT impeded neuronal transmission speed. These 
result  in  a  slowing  and  disorganization  of  cognitive  processing  that  was  manifested  in 
neurocognitive deficits [18]. Children with leukemia spend considerable time in the hospital, 
miss significant amounts of school, tire more easily than healthy children, and are restricted in 
the more active aspects of learning. These factors have been related to lowered performance on 
IQ tests,  particularly  on Weschlers  Intelligence Scale  – Revised(WISC-R)  subtests  with a 
strong educational component [19]. 
Systemic methotrexate in high doses and combined with radiation therapy can lead to a 
well-described leukoencephalopathy, in which severe neurocognitive deficits are obvious. The 
deleterious  effects  of  systemic  methotrexate,  especially  at  doses  above  1  g/m2 may  be  no 
different or worse than those of 18 Gy of cranial radiation therapy [20] At lower methotrexate 
doses, there does not appear to be a consistent pattern of neurocognitive deficits [21].  One 
long-term  study  of  infants  who  received  high-dose  systemic  methotrexate  combined  with 
intrathecal cytarabine and methotrexate for CNS leukemia prophylaxis and who were tested 3 
to 9 years posttreatment showed that cognitive function was in the average range.[22]
Chemotherapy alone for ALL may result in cognitive dysfunction. One study examined 
48 children treated for leukemia without cranial radiation therapy and found impairment in 
tasks of higher-order cognitive functioning and learning disabilities in the area of mathematics.
[20] Another study showed that children, particularly females, treated with systemic and IT 
methotrexate for CNS leukemia prophylaxis showed impairment of verbal memory and coding.
[23]. 
Table 5 CNS late effects
Late Effect Causative Treatment
Signs and 
Symptoms
Screening and 
Diagnostic Tests
Management 
and Intervention
Neurocognitive 
deficit 
Chemotherapy: 
High-dose IV 
methotrexate, IT 
methotrexate
Difficulty with: 
reading, language, 
verbal and 
nonverbal 
memory, 
arithmetic, 
receptive and 
expressive 
language, 
attention deficit, 
decreased IQ, 
Neurocognitive 
testing: psycho-
educational, 
neuropsychologic
Psychoeducation 
assistance 
Radiation: >18 
Gy
Leuko-
encephalopathy 
Chemotherapy: 
methotrexate: IT 
or IV, IT 
cytarabine 
Seizures, 
neurologic 
impairment, 
compare with 
premorbid status 
Computed 
tomography (CT)/
magnetic resonance 
imaging (MRI) 
scan baseline and 
symptoms 
Symptom 
management: 
muscle relaxants, 
anticonvulsants, 
physical therapy, 
occupational 
therapy
Late Effect Causative Treatment
Signs and 
Symptoms
Screening and 
Diagnostic Tests
Management 
and Intervention
Radiation: >18 
Gy (with 
methotrexate) 
Focal necrosis Chemotherapy: 
methotrexate: IT 
or high-dose IV 
carmustine 
(BCNU), cisplatin 
Headaches, 
nausea, seizures, 
papilledema, 
hemiparesis/other 
focal findings, 
speech, learning, 
and memory 
deficits 
CT/MRI scan 
baseline, as needed 
for symptoms, 
positron emission 
tomography or 
single photon 
emission computed 
tomography scan
Steroid therapy, 
debulking of 
necrotic tissue
Radiation: >50 
Gy (especially 
with >2 Gy daily 
fraction) 
Surgery: 
Resection of 
tumor 
Vision loss Radiation: >50 
Gy (optic nerve 
chiasma) 
Progressive visual 
loss 
Ophthalmic 
evaluation, visual-
evoked response 
Visual aids 
Ototoxicity Chemotherapy: 
CDDP, 
carboplatin 
Abnormal speech 
development, 
hearing 
Audiogram 
baseline 
Speech therapy, 
hearing aid
Myelitis Radiation: 
>45-50 Gy
Paresis, spasticity, 
altered sensation, 
loss of sphincter 
control 
MRI Steroids, physical 
therapy, 
occupational 
therapy 
Surgery: Spinal 
cord surgery 
TABLE-6 Neurocognitive outcome in survivors of pediatric cancer [23]
Psychosocial 
Many  childhood  cancer  survivors  have  adverse  quality  of  life  or  other  adverse 
psychologic  outcomes.  Incorporation  of  psychological  screening  into  clinical  visits  for 
childhood  cancer  survivors  may  be  valuable;  however,  limiting  such  evaluations  to  those 
returning to long-term follow-up clinics may result in a biased subsample of those with more 
difficulties, and precise prevalence rates may be difficult to establish. A review of behavioral, 
emotional, and social adjustment among survivors of childhood brain tumors illustrates this 
point, in whom rates of psychological maladjustment range from 25% to 93% [24].
Studies  in  the  early  1990s  described  childhood  cancer  survivors  as  generally  well 
adjusted, though a subset had psychological difficulties that resulted in functional impairment 
[25].  Further  in-depth analyses have led to  the  description  of  posttraumatic  stress  disorder 
(PTSD) in some childhood cancer survivors and their  mothers.  The core features of PTSD 
include:[26]  experiencing  an  event  perceived  as  life  threatening,  with  an  accompanying 
reaction  of  intense  fear,  horror,  or  helplessness,  persistent  re-experiencing  of  the  event, 
avoiding things, events, or people surrounding the event or decreased responsiveness to same, 
increased sleep disturbance, irritability, hypervigilance, and difficulty in concentrating.
Because avoidance of places and persons associated with the cancer is part of PTSD, the 
syndrome may interfere with obtaining appropriate health care. Those with PTSD perceived 
greater current threats to their lives or the lives of their children. Other risk factors include poor 
family functioning, decreased social support, and noncancer stressors. One study of 78 young 
adult survivors of childhood cancer found 20.5% met the criteria for PTSD. In contrast, only 
4.5% of younger children met the criteria for the syndrome [27].
In a study of 101 adult cancer survivors of childhood cancer, psychologic screening was 
performed at  the survivorship clinic at  the Dana Farber Cancer Institute.  On the Symptom 
Checklist  32 subjects had a positive screen (indicating psychological distress), and 14 subjects 
reported at least 1 suicidal symptom. Risk factors for psychological distress included subjects’ 
dissatisfaction  with  physical  appearance,  poor  physical  health,  and  treatment  with  cranial 
radiation. In this study, the instrument was shown to be feasible in the setting of a clinic visit 
because the psychological screening was completed in less than 30 minutes [28]. In a recent 
study  reported  from India  behaviour  and  adjustment  problems  were  noted  among  20% of 
childhood cancer survivors and depression was noted among 27% of subjects [29].
Special Senses 
Hearing 
Hearing loss is a common late effect of survivors of CNS cancers and cancers of the 
head  and  neck who received  high  doses  of  radiation  therapy  and  platinum chemotherapy. 
Hearing  loss  in  the  speech  range  (0.5  kHz  to  3  kHz),  which  may  compromise  language 
reception and expression, is reported with cumulative doses of cisplatin greater than 360mg/m2, 
and  25% prevalence  of  hearing  loss  is  reported  with  doses  greater  than  720 mg/m2.  Fifty 
percent of  children treated with cisplatin doses greater  than 450 mg/m2 have sensorineural 
hearing  loss  (SNHL)  in  the  high  frequencies  (6  kHz  to  8  kHz).  Younger  age  at  time  of 
administration increases risk [30]. Radiation therapy can result in cochlear damage, with SNHL 
occurring in about 25% of patients treated with doses approaching 60 Gy [31]. The sequence of 
chemoradiotherapy appears to influence risk. Risk and severity of ototoxicity are greater when 
cisplatin is administered after cranial radiation.[32] 
Optic and Orbital 
Orbital complications are common following radiation therapy for childhood head and 
neck sarcomas, CNS tumors, and retinoblastoma and as part of total-body irradiation (TBI).
For  survivors  of  retinoblastoma,  a  small  orbital  volume  may  result  from  either 
enucleation or radiation therapy. Age younger than 1 year may increase risk, but this is not 
consistent across studies. Treatment for tumors located near the macula and fovea increase risk 
of complications leading to visual loss [32]. 
Survivors  of  orbital  rhabdomyosarcoma  are  at  risk  of  dry  eye,  cataract,  orbital 
hypoplasia,  ptosis,  retinopathy,  keratoconjunctivitis,  optic  neuropathy,  lid  epithelioma,  and 
impairment of vision following radiation therapy doses of 30 Gy to 65 Gy. The higher dose 
ranges  (>50  Gy)  are  associated  with  lid  epitheliomas,  keratoconjunctivitis,  lacrimal  duct 
atrophy, and severe dry eye. Retinitis and optic neuropathy may also result from doses of 50 
Gy to 65 GyCataracts are reported following lower doses of 10 Gy to 18 Gy [33]. 
Patients  treated  with  TBI  are  also  at  increased  risk  of  cataracts.  Risk  ranges  from 
approximately  10%  to  60%  at  10  years  posttreatment,  depending  on  the  total  dose  and 
fractionation, with a shorter latency period and more severe cataracts noted after single fraction 
and higher dose or dose-rate TBI. Corticosteroids and graft-versus-host-disease (GVHD) may 
further increase risk [34].
Table 7. Eye Late Effects
Late Effect
Causative 
Treatment
Signs and 
Symptoms
Screening and 
Diagnostic Tests
Management and 
Intervention
Lacrimal glands: 
decreased tear 
production
Radiation: 
>50 Gy
Dry, irritated red 
eye, foreign-body 
sensation, positive 
fluorescein staining
Penlight/slit lamp 
exam, fluorescein 
staining
Tear replacement, 
occlude lacrimal 
puncta, education 
regarding avoiding 
rubbing lids when 
puncta plug is intact
Cornea: ulceration Radiation: 
>45 Gy
Pain, foreign-body 
sensation, decreased 
visual acuity, 
photosensitivity
Slit lamp/penlight 
exam, fluorescein 
staining
Tear replacement, 
antibiotics, soft 
bandages, soft contact 
lens, surgery, 
ophthalmology
Neovascularization Radiation: 
>50 Gy
Increased tearing, 
increased vessels 
surrounding edge of 
cornea
Slit lamp exam Tear replacement, 
antibiotics, soft 
bandages, soft contact 
lens, surgery, 
Lens: cataract Chemotherap
y: Steroids)
Decreased visual 
acuity, opaque lens
Direct 
ophthalmoscopic 
exam, decreased 
red reflex, slit 
lamp/penlight 
exam: opaque lens
Prevention by 
shielding during 
treatment, surgical 
removal, educate 
regarding UV 
protection
Radiation: 
>10-15 Gy 
(fractionated)
Secondary 
glaucoma
— Eye pain, headache, 
nausea/vomiting, 
decreased 
peripheral vision, 
increased 
intraocular pressure 
Measure ocular 
pressure
Beta blocker drops, 
atropine, 
acetazolamide 
(Diamox)
Atrophy Radiation: 
>50 Gy
Decreased iris 
stroma at pupillary 
margin
Slit lamp/penlight 
exam
Photocoagulation
Hemorrhage Radiation: 
>50 Gy
— Visual acuity,, 
fundus 
photography
Steroids, 
photocoagulation, 
Optic neuropathy Radiation: 
>50 Gy
Pale optic disc, 
abnormal pupillary 
responses
Visual evaluation Visual aids
Digestive System
Dental 
Both chemotherapy and radiation therapy can cause multiple cosmetic and functional 
abnormalities of dentition, most predominantly in children treated before age 3 years who have 
not yet developed deciduous dentition.
Doses of 20 Gy to 40 Gy can cause root shortening or abnormal curvature, dwarfism, 
and hypocalcification [35]. More than 85% of survivors of head and neck rhabdomyosarcoma 
who receive radiation doses greater  than 40 Gy may have significant dental  abnormalities, 
including mandibular or maxillary hypoplasia, increased caries, hypodontia, microdontia, root 
stunting, and xerostomia. Chemotherapy for the treatment of leukemia can cause shortening 
and  thinning  of  the  premolar  roots  as  well  as  enamel  abnormalities  [36]. Salivary  gland 
irradiation  incidental  to  treatment  of  head and neck malignancies  or  Hodgkin’s  lymphoma 
causes a qualitative and quantitative change in salivary flow, which can be reversible after 
doses of less than 40 Gy but may be irreversible after higher doses. Dental caries are the most 
problematic consequence. The use of topical fluoride can dramatically reduce the frequency of 
caries, and saliva substitutes and sialagogues can ameliorate sequelae such as xerostomia [37].
Hepatic 
Most  chemotherapy  agents  employed  in  childhood  cancer  therapy  can  have  acute 
hepatotoxic effects. In the modern era, long-term hepatic effects following chemotherapy alone 
are  uncommon Cumulative  dose,  volume of  liver  irradiated,  and  additional  treatment  with 
chemotherapy are important risk factors for hepatic fibrosis. Radiation hepatopathy can occur 
with doses of 30 Gy to 40 Gy to the entire liver [38]. 
Patients who received blood transfusions before 1992 are at increased risk of developing 
hepatitis C infection. Those infected may then progress to chronic active hepatitis and cirrhosis, 
and have an increased risk of developing hepatocellular carcinoma. The incidence risks range 
widely from 6% to 49% across studies, but may likely be in the 20% to 25% range overall [39]. 
Therefore, all  children who received blood transfusions before 1992 should be screened for 
hepatitis  C virus.  Those  found  to  be  positive  should  be  referred  to  gastroenterologists  for 
consideration of therapy in ongoing studies.
Digestive Tract 
Late radiation injury to the digestive tract is attributable to vascular injury. Necrosis, 
ulceration, stenosis or perforation can occur and are characterized by malabsorption, pain, and 
recurrent episodes of bowel obstruction, as well as perforation and infection [40]. Doses greater 
than  40  Gy  are  required  to  cause  bowel  obstruction  or  chronic  enterocolitis.Sensitizing 
chemotherapeutic agents such as dactinomycin or anthracyclines can increase this risk [41].
Table 8 Gastrointestinal (GI) Late Effects
Late 
Effects
Causative 
Treatment
Signs and 
Symptoms
Screening and Diagnostic 
Tests
Management and 
Intervention
Enteritis Chemotherapy: 
actinomycin D and 
doxorubicin 
(enhance radiation 
therapy effect)
Abdominal 
pain, diarrhea, 
decreased stool 
bulk, emesis, 
weight loss, 
poor linear 
growth
Height and weight every 
year, stool guaiac every 
year, complete blood count 
(CBC) with mean 
corpuscle volume (MCV) 
every year, total protein & 
albumin every 3-5 years 
(absorption tests, vitamin 
B12 level, and contrast 
studies)
Dietary 
management, refer 
to 
gastroenterologist
Radiation: >40 
Gy
Surgery: 
Abdominal surgery 
enhances RT effect
Adhesions Radiation: 
Radiation 
enhances effect
Abdominal 
pain, bilious 
vomiting, 
hyperactive 
bowel sounds
Abdominal radiograph Nothing by mouth, 
gastric suction, 
adhesion lysis
Surgery: 
Laparotomy
Fibrosis: 
esophagus 
(stricture)
Chemotherapy: 
actinomycin D and 
doxorubicin 
Weight loss, 
dysphagia, 
poor linear 
growth
Height and weight every 
year, CBC every year, 
(barium 
swallow/endoscopy as 
needed)
Esophageal 
dilation, antireflux 
surgery
Radiation: >40-50 
Gy
Surgery: 
Abdominal surgery
Fibrosis: 
small 
intestines
Radiation: >40 
Gy 
Diarrhea, 
weight loss, 
obstruction, 
abdominal 
pain, 
constipation
Height and weight every 
year, CBC with MCV 
every year, serum protein 
& albumin every 3-5 years 
(upper GI, small bowel 
biopsy)
High-fiber diet, 
decompression, 
resection, balloon 
dilation
Surgery: 
Abdominal surgery
Late 
Effects
Causative 
Treatment
Signs and 
Symptoms
Screening and Diagnostic 
Tests
Management and 
Intervention
Fibrosis: 
large 
intestine, 
colon
Radiation: >40 
Gy 
Abdominal 
colic, rectal 
pain, 
constipation, 
melena, weight 
loss, 
obstruction 
Height and weight every 
year, rectal exam, stool 
guaiac every year, lower 
GI, colonoscopy, 
sigmoidoscopy
Stool softeners, 
high-fiber diet
Surgery-
Abdominal surgery
Immune System
Spleen 
Splenectomy increases risk of life-threatening invasive bacterial infection [42]. It is no 
longer standard practice to perform a staging laparotomy for pediatric Hodgkin’s lymphoma. 
Therefore,  the  previously  described  long-term  complications,  related  to  both  surgery  and 
altered immune function, should no longer be an issue for most survivors of childhood cancer 
[43]. Children may be rendered asplenic by radiation therapy to the spleen in doses greater than 
30 Gy, however, given as involved-field irradiation or as part of nodal irradiation [44]. 
For  patients  with  surgical  or  functional  asplenia,  prophylactic  antibiotics  (generally 
penicillin) are recommended as daily lifelong treatment. No randomized studies that address 
the benefit of antibiotics have been conducted in a pediatric oncology population; thus, these 
recommendations are based on any pediatric population with asplenia [45]. As a result, some 
patients,  over  time,  discontinue  use  of  antibiotics.  In  these  cases,  antibiotics—generally 
penicillin—should be taken at the first  onset of febrile illness if the patient is not on daily 
prophylaxis. Medical care should be sought promptly for fevers higher than 38.5° C. Patients 
should  receive  antibiotic  prophylaxis  for  dental  work  and  should  be  immunized  against 
meningococcus, hemophilus influenzae type B, and Streptococcus pneumoniae[42]. 
Circulatory System
Cardiovascular 
Childhood  cancer  survivors  exposed  to  anthracyclines  (doxorubicin,  daunorubicin, 
idarubicin,  epirubicin,  mitoxantrone)  or  thoracic  radiation therapy are at  risk for  long-term 
cardiac toxicity. The risks to the heart are related to cumulative anthracycline dose, method of 
administration,  amount  of  radiation  delivered  to  different  depths  of  the  heart,  volume and 
specific  areas  of  the  heart  irradiated,  total  and fractional  irradiation dose,  age at  exposure, 
latency period, and gender. 
The  effects  of  thoracic  radiation  therapy  are  difficult  to  separate  from  those  of 
anthracyclines  because  few children  undergo  thoracic  radiation  therapy without  the  use  of 
anthracyclines. The pathogenesis of injury differs, however, with radiation primarily affecting 
the fine vasculature of the heart and anthracyclines directly damaging myocytes.[] Late effects 
of radiation to the heart include delayed pericarditis ,pancarditis, which includes pericardial and 
myocardial  fibrosis,  with  or  without  endocardial  fibroelastosis,  myopathy.  coronary  artery 
disease (CAD), functional valve injury and conduction defects [46].
In a study of 635 patients treated for childhood Hodgkin’s lymphoma, the actuarial risk 
of pericarditis requiring pericardiectomy was 4% at 17 years posttreatment (occurring only in 
children  treated  with  higher  radiation  doses).  Only  12  patients  died  of  cardiac  disease, 
including 7 deaths from acute myocardial infarction; however, these deaths occurred only in 
children treated with 42 Gy to 45 Gy(N121) Among children treated with 15 Gy to 26 Gy, none 
developed radiation-associated  cardiac  problems [47].  Increased  risk of  doxorubicin-related 
cardiomyopathy is associated with female sex, cumulative doses greater than 200 mg/m2 to 300 
mg/m2,  younger age at time of exposure,  and increased time from exposure [48].  Route of 
administration of doxorubicin may influence risk of cardiomyopathy Earlier studies in adults 
have  shown  decreased  cardiotoxicity  with  prolonged  infusion;  [49],  but  in  a  pediatric 
population  one  study  looked  at  the  effect  of  continuous  (48-hour)  versus  bolus  (1-hour) 
infusions of doxorubicin in 121 children who received a cumulative dose of 360 mg/m2 for 
treatment of ALL and found no difference in the degree or spectrum of cardiotoxicity in the 2 
groups [50]. 
Prevention  or  amelioration  of  anthracycline-induced  cardiomyopathy  is  clearly 
important  because  the  continued  use  of  anthracyclines  is  required  in  cancer  therapy. 
Dexrazoxane  (DZR)  is  a  bisdioxopiperazine  compound  that  readily  enters  cells  and  is 
subsequently hydrolyzed to form a chelating agent. Evidence supports its capacity to mitigate 
cardiac toxicity in patients treated with anthracyclines [51]. 
Rhythm disturbances are also reported after doxorubicin exposure. One study looked at 
electrocardiograms  (ECGs)  in  52  long-term  survivors  of  childhood  cancer  who  had  been 
treated with anthracyclines. Prolongation of corrected QT interval (QTc) of more than 0.43 was 
noted in 6 of 22 patients who had received cumulative anthracycline doses greater than 300 mg/
m2, as compared with 0 of 15 patients who had received lower anthracycline doses [52].
Table 9-Cardiac Late Effects
Late Effects  Causative Treatment  
Signs and 
Symptoms  
Screening and 
Diagnostic Tests  
Management 
and 
Intervention  
Cardiomyopathy Chemotherapy: 
anthracycline >300 
mg/m2, >200 mg/m2 
and radiation therapy 
to mediastinum, 
high-dose 
cyclophosphamide, 
(bone marrow 
transplant [BMT]) 
(possibly ifosfamide) 
Fatigue, cough, 
dyspnea on 
exertion, 
peripheral edema, 
hypertension, 
tachypnea/rales, 
tachycardia, 
cardiomegaly 
(S3/S4), 
hepatomegaly, 
syncope, 
palpitations, 
arrhythmias
ECG, 
echocardiogram/ 
radionuclear 
angiography and 
chest x-ray 
baselines, every 
2-5 years 
(depending on risk 
factors), Holter 
monitor and 
exercise testing 
baseline, as needed 
for symptoms and 
after high 
cumulative 
anthracycline dose 
(>300 mg/m2)
Diuretics, 
digoxin, afterload 
reduction, 
antiarrhythmics, 
cardiac transplant, 
education 
regarding risks of: 
isometric 
exercises, alcohol 
consumption, 
drug use, 
smoking, 
pregnancy, 
anesthesia
Radiation: >35 Gy
Chemotherapy and 
Radiation: >25 Gy 
and anthracyclines
Valvular damage 
(mitral/tricuspid 
aortic)
Radiation: >40 Gy Weakness, cough, 
dyspnea on 
exertion, new 
murmur, 
pulsating liver
Echocardiogram 
and chest x-ray 
(baseline), every 
3-5 years then as 
needed for 
symptoms
Penicillin 
prophylaxis for 
surgery/dental 
procedures
Pericardial 
damage
Radiation: >35 Gy Fatigue, dyspnea 
on exertion, chest 
pain, cyanosis, 
ascites, peripheral 
edema, 
hypotension, 
friction rub, 
muffled heart 
sounds, venous 
distension, pulsus 
paradoxus
ECG (ST-T 
changes, decreased 
voltage), 
echocardiogram, 
chest x-ray 
baseline, every 3-5 
years
Pericardial 
stripping
Coronary artery 
disease
Radiation: >30 Gy Chest pain on 
exertion (radiates 
to arm/neck), 
dyspnea, 
diaphoresis, 
pallor, 
hypotension, 
arrhythmias
ECG every 3 
years, stress test 
(consider thallium 
scintigraphy) 
baseline, every 3-5 
years or as needed 
for symptoms
Diuretics, cardiac 
medications, low-
sodium, low-fat 
diet, conditioning 
regimens
A  number  of  studies  have  examined  cardiac  function  after  radiation  therapy  and 
anthracycline  exposure  using  cardiopulmonary  exercise  stress  tests  and  have  found 
abnormalities in exercise endurance, cardiac output, aerobic capacity, echocardiography during 
exercise testing, and ectopic rhythms [53].
Respiratory System
Pulmonary 
Pulmonary fibrotic disease is seen as a late complication of radiation therapyChanges in 
lung function have been reported in children treated with whole-lung radiation therapy for 
metastatic Wilms’ tumor. A dose of 12 Gy to 14 Gy reduced total lung capacity and vital 
capacity to about 70% of predicted values,] Administration of bleomycin alone can produce 
pulmonary  toxicity  and,  when  combined  with  radiation  therapy,  can  heighten  radiation 
reactionsThe  development  of  bleomycin-associated  pulmonary  fibrosis  with  permanent 
restrictive disease is dose dependent, usually occurring at doses greater than 200 U/m2 to 400 
U/m2,  higher  than  those  used  in  pediatric  malignancies  [54].  A  study  evaluated  serial 
pulmonary  function  in  children  treated  with  COP  (cyclophosphamide,  vincristine,  and 
prednisone)/ABVD and mantle radiation therapy and found 65% to 73% to have only mildly 
decreased or normal diffusing capacity [55]. One other study reviewed pulmonary toxicity in 
survivors of childhood ALL, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma (NHL) and 
found some abnormalities as measured by pulmonary function testing [56].
Bronchiolitis obliterans with or without organizing pneumonia, diffuse alveolar damage, 
and interstitial pneumonia may occur as a component of this syndrome, generally between 6 
and 12 months posttransplant.  Cough, dyspnea,  or wheezing may occur with either normal 
chest x-ray or diffuse/patchy infiltrates; however, most patients are symptom free [57]. 
An analysis of self-reported pulmonary complications of 12,390 survivors of common 
childhood malignancies has been reported by the CCSS. This cohort includes children treated 
with both conventional and myeloablative therapies. Compared with siblings, survivors had an 
increased relative risk (RR) of lung fibrosis, recurrent pneumonia, chronic cough, pleurisy, use 
of supplemental oxygen therapy, abnormal chest wall, exercise-induced shortness of breath and 
bronchitis,  with  RRs  ranging  from  1.2  to  13.0  (highest  for  lung  fibrosis  and  lowest  for 
bronchitis). The 25-year cumulative incidence of lung fibrosis was 5% for those who received 
chest radiation therapy and less than 1% for those who received pulmonary toxic chemotherapy 
[58]. 
Urinary System
Renal 
Cisplatin at doses greater than 200 mg/m2 can result in glomerular or tubular injury and 
renal  insufficiency.  Other  nephrotoxic  agents  such  as  aminoglycosides,  amphotericin,  and 
ifosfamide may further increase risk. Ifosfamide can also cause glomerular and tubular toxicity, 
with renal tubular acidosis, and Fanconi’s syndrome. Doses greater than 60 g/m2 to 100 g/m2, 
age younger than 5 years at time of treatment, and combination with cisplatin and carboplatin 
increase risk [59].
Radiation nephropathy is dose-related. Doses greater than 25 Gy to both kidneys can 
cause renal failure at delayed intervals of more than 6 months [60].  One study examined the 
spectrum of renal failure in 55 patients among the 5,823 patients treated for Wilms’ tumor. The 
incidence  of  renal  failure  at  16  years  postdiagnosis  was  0.6% for  patients  with  unilateral 
disease  and 13% for  patients  with  bilateral  disease.  The most  common etiologies  of  renal 
failure were bilateral nephrectomy for persistent or recurrent tumor, progressive tumor in the 
remaining kidney without nephrectomy, Denys-Drash syndrome (DDS), and radiation nephritis 
[61]. In another study from the National Wilms’ Tumor Group of children treated from 1969 to 
1995, 58 of 5,976 developed renal failure with a median follow-up of 11 years. Patients with 
bilateral disease and unilateral disease had a 20-year renal failure incidence of 5.5% and 1.0%, 
respectively.
In  the  setting  of  HSCT,  fewer  than  15%  of  children  will  develop  chronic  renal 
insufficiency or hypertension; the risk is related to the nephrotoxic agents used and the TBI-
fractionation scheme and interfraction interval [57].
Table 10 Kidney and Bladder Late Effects
Late Effects  
Causative 
Treatment  
Signs and 
Symptoms  
Screening and 
Diagnostic Tests   
Management and 
Intervention  
Glomerular 
dysfunction
Chemotherapy: 
cisplatin, carboplatin
Asymptomatic or 
fatigue, poor 
linear growth, 
anemia, oliguria
Annual: blood 
pressure, height, 
weight, 
hemoglobin/ 
hematocrit, 
urinalysis, 
creatinine, BUN; 
creatinine 
clearance baseline 
and every 3 years
Low-protein diet, 
dialysis, renal 
transplant
Tubular 
dysfunction
Chemotherapy: 
cisplatin, 
carboplatin, 
ifosfamide 
Seizures 
(↓magnesium 
[Mg]), weakness 
(↓phosphate 
[PO4]), 
glycosuria, poor 
linear growth
Annual: blood 
pressure, height, 
weight, 
hemoglobin/ 
hematocrit, 
urinalysis, 
creatinine, BUN; 
creatinine 
clearance baseline 
and every 3 years 
and Mg, PO4 (24-
hour urine for 
calcium, PO4)
Mg supplement, 
PO4 supplement
Bladder: 
fibrosis or 
hypoplasia 
(reduced 
bladder 
capacity)
Chemotherapy: 
cyclophosphamide, 
ifosfamide 
Urgency, 
frequency, 
dysuria, 
incontinence 
(nocturia), pelvic 
hypoplasia
Urinalysis every 
year (cystoscopy, 
intravenous 
pyelogram/ 
ultrasound [US] : 
volumetrics)
Exercises to 
increase bladder 
capacity, surgical 
referral
Radiation: >30 Gy 
prepubertal, >50 Gy 
postpubertal
Hemorrhagic 
cystitis
Chemotherapy: 
cyclophosphamide, 
ifosfamide 
Hematuria, 
frequency, 
urgency, dysuria, 
bladder 
tenderness
Urinalysis every 
year to rule out 
urinary tract 
infection (UTI), 
renal calculi 
(cystoscopy if 
hematuria on 2 
exams)
Transfusion, 
antispasmodics, 
formalin, counsel 
regarding risk of 
bladder cancer
Radiation: 
(Radiation enhances 
chemotherapy 
effect)
Thyroid Gland 
Thyroid dysfunction, manifested by primary hypothyroidism, hyperthyroidism, goiter, 
or nodules, is a common delayed effect of radiation therapy fields that include the thyroid gland 
incidental to treating Hodgkin’s lymphoma, brain tumors, head and neck sarcomas, and ALL. 
Of children treated with radiation therapy, most develop hypothyroidism within the first 2 to 5 
years  posttreatment,  but  new  cases  can  occur  later.  Reports  of  thyroid  dysfunction  differ 
depending  on  the  dose  of  radiation,  the  length  of  follow-up,  and  the  biochemical  criteria 
utilized to make the diagnosis [62].
In a study of 1,677 children and adults with Hodgkin’s lymphoma who were treated with 
radiation therapy between 1961 and 1989, the actuarial risk at 26 years posttreatment for overt 
or subclinical hypothyroidism was 47%, with a peak incidence at 2-3 years posttreatment [63]. 
In a study of Hodgkin’s lymphoma patients treated between 1962 and 1979, hypothyroidism 
occurred in 4 of 24 patients who received mantle doses less than 26 Gy but in 74 of 95 patients 
who received greater than 26 Gy. The peak incidence occurred at 3 to 5 years posttreatment, 
with a median of 4.6 years [64].
Table 11 Thyroid Late Effects
Late Effects
Causative 
Treatment
Signs and 
Symptoms
Screening and 
Diagnostic Tests
Management 
and 
Intervention
Overt 
hypothyroidism 
(elevated TSH, 
decreased T4)
Radiation: >20 
Gy to the neck, 
cervical spine
Hoarseness, fatigue, 
weight gain, dry 
skin, cold 
intolerance, dry 
brittle hair, alopecia, 
constipation, 
lethargy, poor linear 
growth, menstrual 
irregularities, 
pubertal delay, 
bradycardia, 
hypotension
Free T4, TSH annually up 
to 10 years postradiation 
or if symptomatic, plot on 
growth chart
Refer to 
endocrinologist, 
thyroxine 
replacement, 
anticipatory 
guidance 
regarding 
symptoms of 
hyperthyroidism
/ 
hypothyroidism
Radiation: >7.5 
Gy TBI
Surgery: Partial 
or complete 
thyroidectomy
Compensated 
hypothyroidism 
(elevated TSH, 
normal T4)
Same as overt 
hypothyroidism 
with regard to 
radiation and 
surgery
Asymptomatic Free T4, TSH annually up 
to 10 years postradiation 
or if symptomatic, plot on 
growth chart
Refer to 
endocrinologist, 
thyroxine to 
suppress gland 
activity
Thyroid nodules Any dose 
radiation
Hoarseness, fatigue, 
weight gain, dry 
skin, cold 
intolerance, dry 
brittle hair, alopecia, 
constipation, 
lethargy, poor linear 
growth, menstrual 
irregularities, 
pubertal delay, 
bradycardia, 
hypotension
Free T4, TSH annually up 
to 10 years postradiation 
or if symptomatic, plot on 
growth chart, physical 
exam; ultrasound for 
technetium99m scan 
baseline and then as 
needed for symptoms
Refer to 
endocrinologist, 
thyroid scan, 
biopsy/resection
Hyperthyroidism 
decreased TSH, 
elevated T4
Same as overt 
hypothyroidism 
with regard to 
radiation
Nervousness, 
tremors, heat 
intolerance, weight 
loss, insomnia, 
increased appetite, 
diarrhea, moist skin, 
tachycardia, 
exophthalmus, 
goiter
Free T4, TSH annually up 
to 10 years postradiation 
or if symptomatic, plot on 
growth chart physical 
exam; ultrasound for 
technetium99m scan 
baseline and then as 
needed for symptoms, 
triiodothyronine (T3), 
antithyroglobulin, 
antimicrosomal antibody 
baseline, then as needed.
Refer to 
endocrinologist, 
propylthiouracil 
(PTU), propanol 
131I, 
thyroidectomy
Neuroendocrine System 
Other  endocrine  abnormalities  can  occur  after  cranial  irradiation,  including  growth 
hormone (GH) deficiency, delayed or precocious puberty, and hypopituitarism. Hypothalamic 
dysfunction is most common, though pituitary insufficiency may occur [65]. Approximately 
60% to 80% of irradiated pediatric brain tumor patients who have received doses greater than 
30 Gy will  have impaired serum GH response to provocative stimulation, usually within 5 
years of treatment.  The dose-response relationship has a threshold of 18 Gy to 20 Gy; the 
higher the radiation dose, the earlier the GH deficiency will occur after treatment [66].
Children treated with CNS irradiation for leukemia are also at  increased risk of GH 
deficiency.  One study evaluated 127 patients  with ALL treated with 24 Gy,  18 Gy,  or  no 
cranial irradiation. The change in height, compared with population norms expressed as the 
standard deviation score (SDS), was significant for all 3 groups with a dose-response of -0.49 ± 
0.14 for the no radiation therapy group, -0.65 ± 0.15 for the 18 Gy radiation therapy group, and 
-1.38 ± 0.16 for the 24 Gy group [67] Another study found similar results in 118 ALL survivors 
treated with 24 Gy cranial irradiation, in which 74% had SDS score of ≥-1 and the remainder 
≥-2.[68] Pubertal growth can be adversely affected by cranial radiation. Doses greater than 50 
Gy may result in gonadotrophin deficiency, while doses in the range of 18 Gy to 47 Gy can 
result in precocious puberty. Precocious puberty has been reported in some children receiving 
cranial  irradiation,  mostly  in  girls  who receive  doses  greater  than 24 Gy cranial  radiation. 
Earlier puberty and earlier peak height velocity, however, are seen in girls treated with 18 Gy 
cranial  radiation  [69].  Another  study  showed  that  the  age  of  pubertal  onset  is  positively 
correlated with the age at the time of cranial irradiation. The impact of early puberty in a child 
with  radiation-associated  GH  deficiency  is  significant,  and  timing  of  GH  is  especially 
important for GH-deficient females also at risk of precocious puberty. With higher doses of 
cranial irradiation (>35 Gy), deficiencies in the gonadotropins can be seen, with a cumulative 
incidence of 10% to 20% at 5 to 10 years posttreatment [70].
Table 12 Neuroendocrine Late Effects
Late Effects  
Causative 
Treatment  Signs and Symptoms  
Screening and 
Diagnostic Tests  
Management 
and 
Intervention  
GH deficiency Radiation: >18 
Gy to H-P axis
Falling off of growth curve, 
inadequate growth velocity, 
inadequate pubertal growth 
spurt
Annual stadiometer 
height (every 6 
months at age 9-12 
years), growth 
curve, bone age at 9 
years, then every 
year to 
GH therapy, 
delay puberty 
with 
gonadotropin 
releasing 
hormone 
(GnRH) 
agonist
Adrenocorticotropic 
hormone (ACTH) 
deficiency
Radiation: >40 
Gy to H-P axis
Muscular weakness, 
anorexia, nausea, weight 
loss, dehydration, 
hypotension, abdominal pain, 
increased pigmentation (skin, 
buccal mucosa)
Cortisol (a.m.) 
baseline, prn 
symptoms (insulin–
hypoglycemia; 
metapyrone 
stimulation tests)
Hydrocortisone
Surgery: Tumor 
in region of H-P 
axis
Thyrotropin-
releasing hormone 
(TRH) deficiency
Radiation: >40 
Gy H-P axis
Hoarseness, fatigue, weight 
gain, dry skin, cold 
intolerance, dry brittle hair, 
alopecia, constipation, 
lethargy, 
Free T4, T3, TSH 
baseline, every 3-5 
years
Hormone 
replacement 
with thyroxine, 
Precocious puberty 
(especially females)
Radiation: >20 
Gy to H-P axis
Early growth spurt, false 
catch-up, premature sexual 
maturation; female: breast 
development and pubic hair 
before 8 years and menses 
before 9 years; male: 
testicular/penile growth and 
pubic hair before 9-9.5 years
Height, growth 
curve every year, 
bone age every 2 
years until mature, 
(LH, follicle- 
stimulating 
hormone [FSH], 
estradiol or 
testosterone)(pelvic 
ultrasound, GnRH-
stimulation testing)
GnRH agonist
Surgery: Tumor 
in region of H-P 
axis
Gonadotropin deficiency:
Late Effects  
Causative 
Treatment  Signs and Symptoms  
Screening and 
Diagnostic Tests  
Management 
and 
Intervention  
Male Radiation: >40 
Gy to 
hypothalamic 
region
Delayed/ arrested/absent 
pubertal development: lack 
of or diminished pubic and 
axillary hair, penile and 
esticular enlargement, voice 
change, body odor, acne; 
testicular atrophy (softer and 
smaller); failure to 
impregnate 
Tanner stage, LH, 
FSH, estradiol 
every 3-5 years, 
(GnRH testing)
Anticipatory 
guidance 
regarding 
symptoms of 
estrogen 
deficiency, 
hormone 
replacement, 
early 
intervention 
may prevent 
osteoporosis, 
and 
atherosclerosis
Surgery: Tumor 
in region of 
hypothalamus
Female Radiation: >40 
Gy to 
hypothalamic 
region
Delayed/ arrested/ absent 
pubertal development 
including: breasts, female 
escutcheon, female habitus, 
vaginal estrogen effect, body 
odor, acne; changes in 
duration, frequency, and 
character of menstruation 
(less cramping) estrogen 
deficiency: hot flashes, 
vaginal dryness, dyspareunia, 
low libido; infertility (if not 
on birth control pills)
Tanner stage, LH, 
FSH, estradiol 
every 3-5 years, 
GnRH-stimulation 
tests
Anticipatory 
guidance 
regarding 
symptoms of 
estrogen 
deficiency, 
hormone 
replacement, 
early 
intervention 
may prevent 
osteoporosis, 
and 
atherosclerosis
Surgery: Tumor 
in region of 
hypothalamus
Surgery: Tumor 
in region of 
hypothalamus
Metabolic syndrome Chemotherapy: 
Steroids
Obesity, hypertension, 
hyperlipidemia, 
hyperglycemia, insulin 
resistance with 
hyperinsulinemias
Fasting lipids, 
glucose, insulin 
levels, body mass 
index (BMI) 
evaluation
Refer to 
endocrinology
Radiation: 
Questionable 
≥18 Gy (dose 
not well 
established)
Musculoskeletal System
Bone and Body Composition 
Chondroblasts and chondrocytes are affected by radiation therapy in growing children, 
which can result in soft tissue hypoplasia and diminution of bone growth. These effects are 
associated with the total and fractional radiation dose, and the inclusion of the epiphyses in the 
radiation field.[] Craniospinal radiation results in both abnormal GH secretion and effects on 
the vertebral bodies.[71]
Avascular  necrosis  has  been  reported  in  survivors  of  ALL  who  were  treated  by 
conventional therapy or by HSCT, with corticosteroids representing a significant risk factor 
[72]. In the closed CCG 1961 protocol, among 2,077 accrued patients, unifocal osteonecrosis 
was seen in 19 patients, and multifocal disease in 74 [73].
Bone  mineral  density  in  childhood  cancer  survivors  may  be  reduced,  especially  in 
children treated for ALL, in whom it has been best studied. An increased incidence of fractures 
and osteonecrosis also occurs in these patients. Risk factors include increased age at time of 
exposure, estrogen deficiency, female gender, corticosteroid use and type, GH deficiency and 
cranial radiation [74].
Obesity 
Abnormal body composition is also reported in excess in survivors of pediatric ALL. 
One study evaluated obesity in 1,764 ALL survivors followed in the CCSS, and compared 
them with  a  cohort  of  2,565 siblings.  The  odds  ratio  for  being  obese  was  2.6  for  female 
survivors and 1.9 for male survivors who received doses of radiation greater than 20 Gy. The 
highest risk was for females treated at 4 years and younger with cranial radiation doses of 
greater  than 20 Gy.  Risk of  obesity  was  not  increased among ALL survivors  treated with 
chemotherapy  alone  or  with  doses  of  cranial  radiation  of  10  Gy  to  19  Gy  [75].  Genetic 
predisposition may be an important factor in risk for obesity in these ALL survivors. The CCSS 
has found higher BMI to be associated with a polymorphism in the leptin receptor gene [76]. A 
study  from Denmark  reports  reduced  lean  body  mass  among  survivors  of  childhood  non-
Hodgkin’s lymphoma and Hodgkin’s lymphoma [77]. Children treated for brain tumors are at 
risk for development of obesity because of hypothalamic dysfunction resulting from the tumor, 
surgery, or irradiation [78].
A number  of  endocrinologic  and metabolic  findings,  including increased body mass 
index,  can  be  summarized  as  the  metabolic  syndrome.  This  includes  insulin  resistance, 
hyperglycemia, hyperinsulinemia, hypertension, hyperlipidemia, and obesity. It is, at least in 
part, because of disturbances of the H-P axis,
Table 13 Musculoskeletal  Late Effects
Late Effects  Causative Treatment  
Signs and 
Symptoms  
Screening and 
Diagnostic Tests  
Management and 
Intervention  
Muscular 
hypoplasia
Radiation: >20 Gy 
(growing child); 
younger children 
more sensitive
Asymmetry of 
muscle mass 
when compared 
with untreated 
area, decreased 
range of motion, 
stiffness and 
pain in affected 
area 
Careful comparison 
and measurement of 
irradiated and 
unirradiated areas, 
range of motion
Prevention: good 
exercise program, 
range of motion, 
muscle 
strengthening
Surgery: Muscle 
loss or resection
Spinal 
abnormalities: 
scoliosis, 
kyphosis, 
lordosis, 
decreased 
sitting height
Radiation: For 
young children, 
radiation therapy to 
hemiabdomen or 
spine (especially 
hemivertebral); 10 
Gy (minimal effect), 
>20 Gy (clinically 
notable defect)
Back pain, hip 
pain, uneven 
shoulder height, 
rib humps or 
flares, deviation 
from vertical 
curve, gait 
abnormalities
Standing and sitting 
height at each visit 
and plot on chart 
(stadiometer), during 
puberty examine 
spine every 3-6 
months until growth 
is completed and 
then every 1-2 years, 
spinal films baseline 
during puberty, then 
as needed for 
curvature (COBB 
technique to measure 
curvature)
Refer to 
orthopedist if any 
curvature is noted, 
especially during a 
period of rapid 
growth
Surgery: 
Laminectomy
Length 
discrepancy
Radiation: >20 Gy Lower back 
pain, limp, hip 
pain, 
discrepancy in 
muscle mass and 
length when 
compared with 
untreated 
extremity, 
scoliosis
Annual measurement 
of treated and 
untreated limb 
radiograph baseline 
to assess remaining 
epiphyseal growth, 
radiographs annually 
during periods of 
rapid growth
Contralateral 
epiphysiodesis; 
limb-shortening 
procedures
Pathological 
fracture
Radiation: >40 Gy Pain, edema, 
ecchymosis
Baseline radiograph 
of treated area to 
assess bone integrity, 
then as needed for 
symptoms
Surgical repair of 
fracture; may 
require internal 
fixation
Surgery: Biopsy
Osteonecrosis Chemotherapy: 
Steroids
Pain in affected 
joint, limp
Radiograph, CT scan 
as needed for 
symptoms
Symptomatic care; 
joint replacement
Radiation: >40-50 
Gy (more common 
in adults)
Osteopenia/ 
osteoporosis
Chemotherapy: 
Steroids
Fractures, pain DEXA — intervals 
of testing unclear. 
Pediatric norms not 
well established. 
Best data are in 
adults
Calcium 
supplementation, 
increase weight 
bearing exercise; 
refer to 
endocrinology 
Radiation: >18 Gy 
cranial radiation 
therapy 
Reproductive System
Gonadal Function 
Alkylating agents are the chemotherapeutic agents most responsible for gonadal toxicity. 
Male Gonadal Function
Spermatogenesis is highly sensitive to cyclophosphamide, with a dose-effect exhibited 
that is exacerbated by coadministration of other alkylating agents, such as procarbazine [79]. 
With the common use of multiagent therapy that includes cyclophosphamide, sarcoma patients 
are  also  at  increased  risk  of  infertility,  again  with  a  dose  response  effect  Review  of  the 
available  studies  has  led  to  the  consensus  that  males  who  receive  less  than  4  gm/m2 of 
cyclophosphamide without any other alkylating agents and without either testicular or cranial 
radiation are likely to retain their fertility. Doses greater than 9 gm/m2 are unlikely to result in 
any conservation of fertility [80]. 
The  degree  and  permanency  of  radiation  therapy-induced  damage  to  the  male 
reproductive system are dose, field and schedule, and age dependent. The germinal epithelium 
is damaged by much lower doses (<1 Gy) of radiation therapy than are Leydig cells (20 Gy-30 
Gy) [81]. Although temporary oligospermia can occur after these very low radiation doses, 
permanent azoospermia results from higher doses of greater than 3 Gy to 4 Gy. The potential 
for a return of spermatogenesis in the intermediate dose range of 1 Gy to 3 Gy is variable [81].
Female Gonadal Function
Unlike  the  situation  in  males,  hormonal  function  and  potential  for  fertility  are 
synchronous in females. Prepubertal females possess their lifetime supply of oocytes, with no 
new oogonia formed after birth. Risks of menstrual irregularity, ovarian failure, and infertility 
increase with age at  treatment [81].  A study of  2,498 survivors  and 3,509 siblings treated 
between 1945 and 1975, found a 7% fertility deficit among female survivors as compared with 
their  siblings.  Forty-two  percent  of  those  with  alkylating  agent  exposure  and  abdominal 
radiation experienced menopause by age 31 years [82].
The ovary is sensitive to the effects of ionizing radiation. Adverse ovarian effects vary 
depending on factors such as dose, schedule, and age. The younger the child, the larger the 
oocyte pool, and the later the menopause [81]. While radiation doses greater than 8 Gy are 
associated with ovarian ablation, lower doses may not cause infertility.[] Younger girls are 
more resistant than adolescents. Whole abdomen doses of 20 Gy to 30 Gy are associated with 
primary or premature secondary ovarian failureAbdominal radiation therapy at similar doses 
can lead to reduced uterine volume and decreased elasticity, increasing risk of spontaneous 
miscarriage, premature birth, and intrauterine growth retardation [82]. 
Table 14 Male Gonadal Late Effects
Late Effects  Causative Treatment  Signs and Symptoms  
Screening and 
Diagnostic Tests  
Management 
and 
Intervention  
Germ cell 
damage: 
oligospermia/ 
azoospermia
Chemotherapy: 
cyclophosphamide, 
mechlorethamine, lomustine 
(CCNU)/carmustine 
(BCNU), procarbazine, 
ifosfamide, busulfan, 
melphalan, dacarbazine 
(DTIC)
Testicular 
atrophy (softer 
and smaller), 
failure to 
impregnate
Tanner stage, 
inquire regarding 
previous sperm 
banking, 
determine 
testicular size and 
consistency, LH, 
FSH, testosterone: 
(1) for failure of 
pubertal 
development, (2) 
baseline when 
sexually mature, 
(3) for failure to 
impregnate (repeat 
every 3 years for 
possible 
recovery), analysis 
of sperm at 
maturity, or for 
failure to 
impregnate (repeat 
every 3-5 years to 
assess recovery)
Instruct on 
testicular self-
examination, 
anticipatory 
guidance 
regarding 
germ-cell 
damage, 
referral to 
reproductive 
endocrinology, 
infertility 
counseling, 
and alternate 
strategies for 
fathering
Radiation: >1-6 Gy
Surgery: Orchiectomy or 
surgical manipulation
Leydig cell 
damage: 
testosterone 
deficiency
Chemotherapy: 
cyclophosphamide/etoposide 
Delayed/ 
arrested/ absent 
pubertal 
development, 
pubic and 
axillary hair 
(female hair 
pattern), lack of 
penile and 
testicular 
enlargement, 
voice change, 
body odor and 
acne, testicular 
atrophy (softer 
and smaller)
LH and 
testosterone at age 
13 years, failure of 
pubertal 
development; 
baseline, if 
sexually mature; 
changes in libido 
or sexual 
performance
Testosterone 
replacement 
and 
anticipatory 
guidance 
regarding 
testosterone 
deficiency
Radiation: >24 Gy to the 
testes (direct or scattered 
from pelvis)
Surgery: Orchiectomy

Table 15 Female Gonadal Late Effects
Late Effects  
Causative 
Treatment  
Signs and 
Symptoms  
Screening and 
Diagnostic Tests  
Management 
and 
Intervention  
Ovarian failure Chemotherapy: 
mechlorethamine
, 
cyclophosphamid
e, procarbazine, 
busulfan, 
melphalan, 
dacarbazine 
(DTIC), 
carmustine 
(BCNU), CCNU, 
ifosfamide 
Delayed/ 
arrested/ absent 
pubertal 
development 
including: 
breasts, female 
escutcheon, 
female habitus, 
vaginal 
estrogen effect, 
development of 
body odor and 
acne, changes 
in duration, 
frequency, and 
character of 
menses 
(cramping), 
estrogen 
deficiency: hot 
flashes, vaginal 
dryness, 
dyspareunia, 
low libido, 
infertility
Tanner stage, LH, FSH, 
estradiol: (1) age 12 yrs, 
(2) failure of pubertal 
development, (3) 
baseline when fully 
mature, (4) as needed for 
symptoms, assess basal 
body temperature 
(midcycle elevation 
suggests ovulation), 
(dehydroepiandrosterone 
[DHEAs] for failure of 
development)
Hormone 
replacement 
(estrogen), 
anticipatory 
guidance 
regarding 
symptoms of 
estrogen 
deficiency and 
early 
menopause, 
referral to 
reproductive 
endocrinology, 
alternate 
strategies for 
parenting, early 
intervention 
(hormone 
replacement 
may prevent 
osteoporosis, 
atherosclerosis)
Radiation: 4-12 
Gy tolerance 
decreases with 
increasing age
Surgery: 
Oophorectomy or 
oophoropexy
Vagina: 
fibrosis/diminished 
growth
Chemotherapy: 
actinomycin D 
and doxorubicin 
enhance radiation 
therapy effect)
Painful 
intercourse, 
vaginal 
bleeding, small 
vaginal vault
Pelvic exam (possibly 
under anesthesia) 
baseline, during puberty 
and as needed for 
symptoms
Dilations, 
reconstructive 
surgery, 
potential need 
for cesarean 
section
Radiation: >40 
Gy
Uterus: 
fibrosis/decreased 
growth
Radiation: >20 
Gy (prepubertal), 
>40-50 Gy 
(postpubertal)
Multiple 
spontaneous 
abortions, low 
birth-weight 
infants, small 
uterus
Pelvic: baseline, puberty, 
then annually
Questionable 
endometrial 
biopsy, counsel 
regarding 
pregnancy
Late Effects  
Causative 
Treatment  
Signs and 
Symptoms  
Screening and 
Diagnostic Tests  
Management 
and 
Intervention  
Ureter: fibrosis Radiation: 
>50-60 Gy
Frequent 
urinary tract 
infections 
(UTIs), pelvic 
hypoplasia, 
hydronephrosis
Urinalysis every year 
(urethrogram)
UTI 
prophylaxis
Reproduction 
With more childhood cancer survivors retaining their fertility, pregnancy outcome data 
are now available. In a study of 4,029 pregnancies among 1,915 women followed in the CCSS, 
there were 63% live births, 1% stillbirths, 15% miscarriages, 17% abortions, and 3% unknown 
or in gestation. Risk of miscarriage was 3.6-fold higher in women treated with craniospinal 
radiation and 1.7-fold higher in those treated with pelvic radiation. Chemotherapy exposure 
alone did not increase risk of miscarriage. Compared with siblings, survivors were less likely to 
have live births,  more likely to have medical abortions, and more likely to have low-birth-
weight babies [83]. 
Another  study evaluated pregnancy outcomes of  partners  of  male  survivors.  Among 
4,106 sexually active males, 1,227 reported they sired 2,323 pregnancies, which resulted in 
69% live births, 13% miscarriages, 13% abortions, and 5% unknown or in gestation at the time 
of analysis. Compared with partners of male siblings, there was decreased risk of live births 
(RR = 0.77), but no significant differences of pregnancy outcome by treatment [84].
In a report of 2,198 offspring of adult survivors treated for childhood cancer between 
1945 and 1975 compared with 4,544 offspring of sibling controls, there were no differences in 
the  proportion  of  offspring  with  cytogenetic  syndromes,  single-gene  defects,  or  simple 
malformations. There was similarly  no effect of type of childhood cancer treatment on the 
occurrence of genetic disease in the offspring. A population-based study of 2,630 live-born 
offspring  of  childhood  cancer  survivors  versus  5,504  live-born  offspring  of  the  survivors' 
siblings  found no differences  in  proportion  of  abnormal  karyotypes  or  incidence of  Down 
syndrome or Turner syndrome between survivor and sibling offspring [85].
Second Malignant Neoplasms 
Several large studies have examined the incidence and spectrum of second malignant 
neoplasms (SMNs) in childhood cancer survivors, in whom the cumulative risk at 20 years 
posttreatment varies from 3% to 10% and is 3 to 20 times greater than that expected in the 
general population. A number of treatment-related risk factors have been identified. Notably, 
radiation  therapy is  associated with the  development  of  solid  tumors  as  well  as  leukemia. 
Alkylating  agents,  platinums,  and  topoisomerase  II  inhibitors  are  associated  with  the 
development  of  leukemia  [86]  Epipodophyllotoxins  are  known  to  increase  the  risk  for 
secondary leukemia, and anthracyclines may also increase this risk after treatment for solid 
tumors [87]. In an analysis of SMN in the Childhood Cancer Survival Study (CCSS), which 
excluded patients with retinoblastoma, the standardized incidence ratio (SIR) was 6.4, with a 
20-year incidence of 3.2% and an absolute excess risk of 1.88 malignancies per 1,000 years of 
patient follow-up. Risk of SMN was elevated for all primary childhood cancer diagnoses, with 
the lowest  SIR reported for non-Hodgkin’s  lymphoma (3.2)  and the highest  for Hodgkin’s 
lymphoma (9.7). Risk was elevated for secondary leukemia, lymphoma, central nervous system 
tumors,  soft  tissue and bone sarcomas,  melanoma, and breast  and thyroid cancer,  with the 
lowest SIR reported for lymphoma (1.5) and the higher SIRs reported for breast cancer (16.2) 
and bone sarcoma (19.1). In multivariate analyses adjusted for radiation exposures, SMNs were 
independently  associated  with  female  sex,  younger  age  at  diagnosis  of  childhood  cancer, 
childhood cancer diagnosis of Hodgkin’s lymphoma, or soft tissue sarcoma and exposure to 
alkylating  agents  [88].  The  CCSS  has  also  reported  an  association  between  gene 
polymorphisms  in  glutathione-S-transferase  M1  (GSTM1),  glutathione-S-transferase  T1 
(GSTT1),  and  XRCC1, and  susceptibility  to  radiation  therapy-related  SMNs  in  childhood 
Hodgkin's lymphoma survivors [89]. The risk of leukemia appears to plateau at 10 to 15 years 
posttherapy, while the risk of second solid malignancies rises with ongoing follow-up, with a 
lifetime risk still unknown.[88]. 
Several studies have examined the risk of SMNs in survivors of Hodgkin’s lymphoma, 
in whom the incidence of secondary breast and thyroid cancer is particularly high. Survivors of 
Hodgkin’s lymphoma are also at increased risk of second leukemia, sarcoma, melanoma, and 
lung, thyroid, and gastrointestinal cancer. 
Patients who undergo bone marrow transplantation have a risk of developing SMNs, 
especially solid tumors. This increased risk has been observed even 20 years posttransplant 
[90].
Patients may be at risk of SMNs by virtue of a cancer predisposition syndrome, which 
also placed them at risk for their primary cancer. This limited population should be targeted for 
education, counseling, and extraordinary surveillance because of their genetic predisposition to 
cancer.[25] This includes children with the genetic form of retinoblastoma. In these individuals, 
the  SMN risk  approaches  50% at  50  years  from treatment  if  they  received  external-beam 
radiation therapy, and 25% at 50 years without previous radiation therapy treatment [91].
Breast cancer at an early age, sarcoma, and other cancers can be expected in children 
with Li-Fraumeni  syndrome or  Li-Fraumeni-like  syndrome [92].  Since hepatoblastoma and 
fibromas have been associated with familial polyposis coli, children with those tumors should 
be examined for the polyposis gene (APC) and screened for colon cancer, as appropriate [93].
Monitoring for Late Effects in Childhood Cancer Survivors
The need for long-term follow-up for childhood cancer survivors is supported by the 
American Society of Pediatric Hematology/Oncology, the International  Society of Pediatric 
Oncology,  and  the  American  Academy  of  Pediatrics.  Survivors  should  seek  care  from 
professionals  with  expertise  in  the  recognition  and  management  of  late  effects  [94]. 
Comprehensive  monitoring  guidelines  for  late  effects  have  been  developed  within  the 
Children’s Oncology Group [95]. 
There is no evidence for the optimum setting for following up long term survivors.Adult 
cancer specialists who may lack the specific training required may not be appropriate to follow 
up childhood cancer survivors.Anticipaton and monitoring   late adverse effects to optimize 
prevention and treatment outcomes requires multidisciplinary expertise, which should include 
one member as the key worker [6].
Table  16 Multidisciplinary follow up team
Adult Oncologist Pediatric neurosurgeon
Clinical psychologist Pediatric oncologist
General practitioner Radiation oncologist
Pediatric endocrinologist Social worker
Pediatric neurologist Specialist nurse
Dentist Optician
Table 17 Scottish guidelines for childhood cancer survivor follow up
Level Treatment Method of 
follow up
Frequency Examples
1 Surgery alone
Low risk 
Postal or 
telephone
1-2 years Wilms tumour 
stage I
chemotherapy
2 Chemotherapy
Low dose cranial 
irradiation ≤ 24 Gy
Nurse or 
primary care-led
1-2 years ALL in 
remission
3 Radiotherapy
HDCT
Medically 
supervised 
follow up clinic
Annual Brain tumours 
Post BMT
FOLLOW UP STRATERGIES
The  degree  and  nature  of  long  term  morbidity  risk  will  depend  on  the  site  of  the 
underlying malignancy, the type and intensity of treatment and age at treatment. Three levels of 
follow  up  groups  are  described  Table17  
[6]
The St Jude model of Long term survivor care
The broad mission of the St Jude After Completion Therapy clinic (ACT) is to improve 
the quality of life of the long term childhood cancer survivor through annual assessment of the 
survivor’s physical and emotional health, social functioning, and educational and vocational 
achievement. Patients who are in remission 5 years after diagnosis and 2 years after completion 
of neoplastic therapy are eligible for transfer to ACT clinic.
Table 18 After completion of therapy interventions to facilitate transition of survivor 
care [96] St Judes model
Nurse practitioner Current health problems
Reproductive status
Psychosocial functioning
Health related QOL
Social Worker Marital status Academic /employment status 
Living arrangements] Maladaptive behaviour
Clinic Nurse Education about breast /testicular self 
examination
Subspeciality provider Consultant assessment as indicated
Physician Review of ACT clinical summary
Review and screening of cancer related health 
risks
Advise for risk reducing behaviours
PATIENTS AND METHODS
PATIENTS AND METHODS
Inclusion criteria
• All subjects who were < 14 years at the time of diagnosis of cancer
• Has completed 3 years of follow up after  primary antineoplastic therapy
• Has completed 5 years of follow up after antineoplastic therapy for relapse 
Exclusion  criteria
• All subjects who were >14 years at the time of diagnosis of cancer
• Subjects who were < 14 years of diagnosis and has not completed 3 years of follow up
• Patients who are receiving antineoplastic therapy
• Patients who had a relapse of their primary malignancy and has not completed 5 years of 
follow up
• Survivors who were  not  willing to provide informed consent  for  enrolment  to  ACT 
clinic or neurocognitive assessment.
Subjects
A  group  of  155  consecutive  long-term  survivors  of  childhood  cancer  have  been 
prospectively studied at the After Completion Therapy (ACT) clinic, medical oncology unit of 
the Cancer Institute (WIA), Chennai, India. 
This included children diagnosed between 1968-2001.All subjects who were ≤ 14 years 
at the time of diagnosis and had completed 3 years follow up were included in the study.
Quality of life analysis was done in 56 subjects and neurocognitive assessment was done 
in 20 survivors of acute lymphoblastic leukemia after written informed consent.
Methods
Evaluation at the ACT clinic included complete history ,anthropometric measurements 
for  each subject and a clinical examination with special emphasis on late toxicities and specific 
investigations to detect organ toxicities as shown in Table-19.Details of the type and doses of 
treatment received were noted.Semen analysis, thyroid hormonal evaluation and sex hormone 
evaluation was done in specific cases at risk. 
Quality  of  life  was  assessed  by  Cancer  Institute  quality  of  life  standardized 
questionnaire  [97].  Dimensions  for  QOL included general  well  being,  physical  well  being, 
psychological well being, interpersonal relationship, sexual and personal ability, cognitive well 
being, optimism and belief, economical well being, informational support, patient physician 
relations ship and body image. 56 childhood cancer survivors were analyzed for their QOL.
Neurocognitive assessment was done in 20 survivors of acute lymphoblastic leukemia 
using Malins Intelligence Scale for Indian children for subjects aged 6 years to 16 years [98]. 
Participants  older  than  16  years  were  administered  the  Wechsler  Adult  Intelligence  Scale-
Revised  (WISA-R)[99]. Indian  adaptation  which  constituted  of  11  sub  tests  -information, 
comprehension, airthmetic, similarities, digit span, vocabulary (verbal scale) and digit symbol, 
picture completion, block design, picture arrangement, object assembly (performance scale)
Subjects were assessed for abstract thinking, reasoning, attention concentration,decision 
making and memory and was classified as per table20.
Table 19 WAIS –Intelligence Classification
WAIS – Score Classification
       ≥130   Very superior
      120-129   Superior
      110-119   Bright normal
      90-109   Average
      80-89   Dull normal
      70-79   Border line
      ≤69   Mental defective
The  subjects  were  also  provided  counseling  and  education  for  healthy  living  and 
referred  to  sub  specialists  if  specific  toxicity  was  detected  In  subjects  who  underwent 
splenectomy specific counseling regarding the risk of severe infections was given.
STUDY PERIOD
May 2004 to May 2006
RESULTS
Of 155 subjects 114 subjects were males.19 subjects had a family history of cancer. 
Pattern of diagnosis was as noted in Table-21
Age distribution showed 90(58%) subjects belonged to the second decade as shown in 
Fig-1 Duration of follow up extended from 3 years to 37 years. Median duration of follow up 
was 8 years and majority (64%) was in the first decade of follow up. (Fig-3)
151(97%) subjects had received chemotherapy, 85(55%) subjects received radiotherapy, 
and 1 subject had high dose chemotherapy and PBSCT. 26 (17%)subjects underwent surgery 
out of which 3 had splenectomy 2 of them had hodgkins lymphoma and 1 acute lymphoblastic 
leukemia, 2 had enucleation and 4 had nephrectomy (Fig-2)
3(1.9%) of male subjects consumed alcohol and 1(0.6%)subject had history of smoking. 
None  of  the  female  subjects  had  history  of  smoking or  alcohol  consumption.  Majority  of 
patients had normal or low normal BMI ,26% and 68 % respectively. Pattern of late effects 
detected in the ACT clinic is noted in Table-22.
Male and female gonadal dysfunction was the most common late toxicity noted (25%). 
Commonest  male gonadal  dysfunction was oligospemia and azzospermia (89 %) while  the 
most common female gonadal dysfunction was amennorhea or oligomenorrhea (78%). All the 
subjects had received combination chemotherapy which included alkylating agents. (fig-5)
7 subjects  had not  attained height  for  age and 4 of  them had received prophylactic 
cranial irradiation. Hypothyroidism was noted in 4of 23 subjects tested for thyroid dysfunction. 
This included 2subject who had Hodgkins lymphoma ,1 subject had Non hodgkins lymphoma 
and  1  subject  was  a  survivor  of  acute  lymphoblastic  leukemia.All  subjects  had  received 
radiotherapy  to  head  and  neck.3  subjects  had  thyroid  profile  suggestive  of  subclinical 
hypothyroidism.
Two second malignant neoplasms were observed among the 155 subjects.
1 year old female child diagnosed to have bilateral retinoblastoma in 1968 and treated 
with external  beam radiotherapy 5000cGY presented in  February  2005 with a  preauricular 
swelling and lymphadenopathy and was diagnosed as ectomesenchymoma of parotid gland.
8 year old boy diagnosed as Hodgkin’s lymphoma stage II A in 1973 underwent staging 
laprotomy  and  treated  with  combination  chemotherapy  and  mantle  field  of  radiotherapy 
presented in May 2005 with dysphagia and was diagnosed to have carcinoma hypopharynx.
Two of the subjects were detected to have cardiovascular dysfunction.17 year old male 
survivor diagnosed as lymphoblastic lymphoma in 1995 and had received anthracycline based 
chemotherapy and irradiation to the mediastinum was detected to have dilated cardiomyopathy 
with congestive cardiac failure.The other subject was a 24 year old male survivor of Hodgkin 
lymohoma who had received subtotal lymph nodal irradiation and was on 16th year of follow. 
He was asymptomatic and incidentally detected to have mitral valvular regurgitation.
Post mantle field radiotherapy lymphedema was noted in one subject. One of the subject 
who is a survivor of ALL had developed avascular necrosis of the head of femur. Two of the 
subjects were noted to have gynaecomstia.
No evidence of cataract was noted among the survivors. 
Quality of life assessment showed high QOL in 31(55.3%) subjects and average QOL in 
21 subjects. (37.5%)
Neurocognitive assessment was done in 20 survivors of acute lymphoblastic leukemia. 
All the survivors had received prophylactic cranial RT (median dose 20 Gy) and 12 doses of 
intrathecal methotrexate as per MCP 841 protocol. The mean age of children in the combined 
group was 17.3 years. Males constituted 93% of the study group. Socioeconomic status (SES) 
was not consistent. Median duration of follow up was 9.3 years. 3 (15%)of the subjects had 
WISA- R score suggestive of mentally deficient IQ(score≤ 69) while 12 (60)% had average IQ.
(score 90-109).
Table21 Pattern of diagnosis among survivors
Diagnosis Number
Acute Lymphoblastic leukemia 50
Hogkins lymphoma 55
Non hodgkins lymphoma 21
Osteosarcoma/soft tissue sarcoma 12
Germ cell tumours 4
Wilms tumour 5
Retinoblastoma 2
Acute myeloid leukemia 2
Others 4
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Fig 1 - age of survivors on follow up at the ACT clinic
Fig-2 Pattern of modality of treatment received among survivors
Fig. 3 Body mass index pattern among childhood cancer survivors
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Fig-5     Pattern of gonadal dysfunction among survivors
Abbreviation 
RMS-rhabdomyosarcoma,NHL-non hodkins  lymphoma, ALL-acute lymphoblastic leukemia ,  HD – hodgkins  
lymphoma
Fig-6Long Term Survivor of Hodgkins Lymphoma with gynaecomazia and neck muscle 
wasting
Fig-4Post Mantle irradiation Lymphedema
Table 22 Pattern of late effects  noted in ACT Clinic
Pattern of late effects         Number of subjects
Under nutrition
Obesity
Impaired male  gonadal dysfunction  
Impaired female gonadal dysfunction
Seroconversion to HBV    
Seroconversion to HCV
Both HBV and HCV
Hypothyroidism
Subclinical hypothyroidism
Second neoplasm
Muskuloskeltal
Lymphedema
Impaired growth pattern
Cardiovascular dysfunction
Dental abnormalities
9(6%)
3(1.9%)
28(25%)
9(22%)
41(26.4%)
38(24.5%)
18(11.6%)
4(17.3%)
3(13%)
2(1.3%)
12(8%)
1(0.6%)
7(5%)
2(1.3%)
25(16.1%)
DISCUSSION
DISCUSSION
The results of our study show that the commonest long term sequalae of therapy was 
impaired reproduction capacity and impaired growth pattern. Obesity was not common and 
majority of the survivors had good quality of life. Limitations of our study included the study 
population did not involve all the long term survivors and included only the survivors who 
agreed to attend the ACT clinic and hormonal evaluation was not carried out in all subjects as 
is the standard in other ACT clinics due to economic considerations.
Severe obesity was noted in 3 of subjects of whom only 1 subject had received cranial 
irradiation.  Majority  of  our  patients  had  a  lower  BMI  and  obesity  was  not  common  as 
compared to western data Obesity is reported in excess in survivors of pediatric ALL. The 
highest risk in a study conducted in the United States was for females treated at 4 years and 
younger with cranial radiation doses of greater than 20 Gy [75]. 
Although growth hormone estimation was not done in our study ,7% of our subjects had 
not attained the height for age and 4 of the subjects had received cranial irradiation. Growth 
hormone (GH) deficiency, delayed or precocious puberty, and hypopituitarism can occur in 
childhood cancer survivors;  hypothalamic dysfunction being the most common abnormality 
noted after cranial irradiation [65]. A study conducted in North America in118 ALL survivors 
treated with 24 Gy cranial irradiation, showed 74% had impaired growth pattern due to growth 
hormone deficiency [68]. 
Impaired  reproduction  capacity  was  the  commonest  long term toxicity  noted  in  our 
study All our subjects who had gonadal dysfunction received alkylating agents.
Alkylating agents, widely used in childhood cancer therapy are the chemotherapeutic 
agents  most  responsible  for  gonadal  toxicity.  Spermatogenesis  is  highly  sensitive  to 
cyclophosphamide,  with  a  dose-effect  exhibited  that  is  exacerbated  by  coadministration  of 
other alkylating agents, such as procarbazine [79]. Furthermore permanent azoospermia results 
from  radiation  doses  of  greater  than  3  Gy  to  4  Gy  [79].  In  females  risks  of  menstrual 
irregularity, ovarian failure, and infertility increase with age at treatment. A Canadian study of 
female childhood cancer  survivors,  have shown increased incidence of  infertility  and early 
menopause [100] . 
Seroconversion rate to HBSAg and HCV was 26% and 25 % compared to a western 
prospective study where the conversion rates were 16% and 3.2% [102]. Improved screening 
for donors has reduced the seroconversion rates in the recent times. This subset of survivors 
may  require  more  close  monitoring  as  they  are  more  at  risk  of  developing  cirrhosis  and 
hepatocellular  carcinoma  None  of  these  subjects  had  features  of  cirrhosis  or  portal 
hypertension on sonographic  study 16 % of  subjects  who had dental  caries  were provided 
dental consultation and appropriate treatment was given Salivary gland irradiation incidental to 
treatment of head and neck malignancies or Hodgkin’s  lymphoma causes a qualitative and 
quantitative change in salivary flow that can result in the development of dental caries[NCI82].
Hypothyridism was noted in 4 of 23subjects in our study. All the subjects had received 
radiation  therapy  to  head  and  neck.  Subclinical  hypothyroidism was  noted  in  3  survivors. 
Incidence  of  thyroid  dysfunction  differ  depending  on  the  dose  of  radiation,  the  length  of 
follow-up,  and the biochemical  criteria  utilized to make the diagnosis  [103].  Screening for 
thyroid function was done only in subjects who were susceptible to hormonal dysfunction
Both cases in this study had received irradiation and second neoplasm developed within 
or adjacent to the field of irradiation. Irradiated survivors had a higher cumulative incidence of 
developing a second neoplasm than nonirradiated survivors in St Judes study [104]. In a recent 
CCS study  it  was  noted  that  the  risk  of  developing  second  malignancy  was  significantly 
elevated  following  all  childhood cancer  diagnosed except  CNS neoplasm and was  highest 
following neuroblastoma and soft tissue sarcoma [105].
3 of subjects had splenectomy. Splenectomy increases risk of life-threatening invasive 
bacterial infection [42]. However in this study no severe or life threatening infections were 
noted. Two of our survivors with retinoblastoma had undergone enucleation . For survivors of 
retinoblastoma, a small orbital volume may result from either enucleation or radiation therapy. 
Age younger than 1 year may increase risk, but this is not consistent across studies. Better 
management  of  prosthetic  implants  and  newer methods  of  delivering  radiation  therapy are 
likely to reduce risk[106].. None of our subjects had developed cataract.
Our  study  showed  average  and  good  quality  of  life  in  93  %  of  survivors  with 
standardized questionnaire although our sample size was small. In a recent series from India, 
severe  psychological  problems  were  encountered  in  12  %  of  survivors.  [29].As  a  group, 
childhood  cancer  survivors  appear  to  be  within  the  normally  expected  range  in  terms  of 
psychosocial adjustment. Additionally a subset had psychological difficulties that resulted in 
functional impairment [107]
Although baseline neurocognitive assessment was not done our study showed significant 
neurocognitive  dysfunction with poor  academic performance in  3  of  20 survivors  of  acute 
lymphoblastic leukemia. This is consistent with previous cross sectional studie[21]
Neurocognitive sequalae in childhood cancer are mainly due to the result of radiation to 
the whole brain or due to intrathecal or high dose methotrexate or cytarabine. Risk factors 
include  increasing  radiation  dose  ,young  age  at  the  time  of  treatment,  combined  chemo 
radiotherapy and female gender.[NCI21]  Deficits in fine motor skills, visual-spatial abilities, 
verbal  and  nonverbal  memory,  psychomotor  speed  and  shifting  of  attention,  auditory 
perception, word fluency, contingency naming, and the ability to follow directions have all 
been reported [7]
CONCLUSION
Conclusion
Long  term morbidity  risks  in  childhood  cancer  survivors  largely  relate  to  treatment 
modality and the challenge remains to improve survival rates whilst reducing the incidence and 
severity of treatment related late effects and to achieve optimal quality of life.
1) This study showed impaired reproduction capacity as the commonest long term sequalae 
with less incidence of obesity and a good quality of life among childhood cancer survivors 
2) Future studies may include more active recruitment of subjects to improve  the 
attendance in ACT clinic.
3) Monitoring for late effects help the oncologist or the physician in making  an  early 
diagnosis and to make corrective interventions and also  help  to  develop  more  safer 
treatment modalities and there by improve the quality of life of long term survivors
4) The information provided by this ongoing study may allow clinicians to  better 
monitor childhood cancer survivors in countries with limited resources.
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